DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Zhu, Jian ^a   Wang, Yuyan ^a   Duan, Jianchun ^a   Bai, Hua ^a   Wang, Zhijie ^a   Wei, Lai ^b   Zhao, Jun ^a   Zhuo, Minglei ^a   Wang, Shuhang ^a   Yang, Lu ^a   An, Tongtong ^a   Wu, Meina ^a   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b NATIONAL EYE INSTITUTE   (United States)

Author keywords

DNA methylation; EGFR TKI; Non small cell lung cancer; Wnt antagonists

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GENOMIC DNA; PLATINUM;

ADULT; AGED; APC GENE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DKK3 GENE; DNA METHYLATION; EPIGENETICS; FEMALE; GENE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SFRP1 GENE; SFRP2 GENE; SFRP5 GENE; SURVIVAL RATE; TREATMENT RESPONSE; WIF1 GENE;

AGED; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA METHYLATION; EYE PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; WNT SIGNALING PATHWAY;

EID: 84866553227     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-80     Document Type: Article

References (36)

1. Cancer statistics, 2008. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. CA Cancer J Clin 2008 58 2 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. J Clin Oncol 2006 24 4539 4544 10.1200/JCO.2005.04.4859 17008692 (Pubitemid 46630948)
3. Progressin understanding the molecular pathogenesis of human lung cancer. Sekido Y, Fong KM, Minna JD, Biochim Biophys Acta 1998 1378 21 F59 9739759
4. Randomized, multinational, phase III study of docetaxel plus patinnum combinations versus vinorelbine plus cisplatin for advanced NSCLC: the TAX326 Study Group. Fossella F, Pereira JR, Pawel JV, Pluzanska A, Gorbounova V, Kaukel E, et al. J Clin Oncol 2003 21 16 3016 3024 10.1200/JCO.2003.12.046 12837811 (Pubitemid 46606280)
5. First-line chemotherapy for advanced-stage non-small cell lung cancer: focus on docetaxel. Ramalingarm S, Clin Lung Cancer 2005 7 77 S82 16384540
6. Non-cross resistant sequential single agent chemotherapy in first-line advanced non-small cell lung cancer patients: results of a phase II study. Surmont V, Aerts JG, Tan KY, Schramel F, Vernhout R, Hoogsteden HC, et al. J Oncol 2009 10.1155/2009/457418
7. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. N Engl J Med 2009 361 10 947 957 10.1056/NEJMoa0810699 19692680
8. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. N Engl J Med 2010 362 25 2380 2388 10.1056/NEJMoa0909530 20573926
9. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Lancet Oncol 2010 11 2 121 128 10.1016/S1470-2045(09)70364-X 20022809
10. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Zhou CC, Wu YL, Chen GY, Feng JF, Liu XQ, Wang CL, et al. Lancet Oncol 2011 8 12 735 742
11. Erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients(P) with epidermal growth factor receptor (EGFR) activating mutations: interim results of the European Tarceva vs chemotherapy (EURTAC) phase III randomized trial. Rosell R, Gervais R, Vergnenegre A, Massuti B, Felip E, Cardenal F, et al. ASCO 2011 bs7503
12. EGF mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. Science 2004 304 1497 1500 10.1126/science.1099314 15118125 (Pubitemid 38720929)
13. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. N Engl J Med 2004 350 2129 2139 10.1056/NEJMoa040938 15118073 (Pubitemid 38637993)
14. EGF receptor gene mutations are common in lung cancers from never -smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. Proc Natl Acad Sci USA 2004 101 13306 13311 10.1073/pnas.0405220101 15329413 (Pubitemid 39209661)
15. Mutations and addiction to EGFR: the Achilles heal of lung cancers? Gazdar AF, Shigematsu H, Herz J, Minna JD, Trends Mol Med 2004 10 10 482 487
16. Biological and clinical implications of EGFR mutations in lung cancer. Mitsudomi T, Kosaka T, Yatabe Y, Int J Clin Oncol 2006 11 3 190 198 10.1007/s10147-006-0583-4 16850125 (Pubitemid 44087117)
17. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. Sequist LV, Bell DW, Lynch TJ, Haber DA, J Clin Oncol 2007 25 5 587 595 10.1200/JCO.2006.07.3585 17290067 (Pubitemid 350002967)
18. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. N Engl J Med 2005 352 786 792 10.1056/NEJMoa044238 15728811 (Pubitemid 40271173)
19. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Engelman JA, Zejnullahu K, Mitsudomi T, Song YC, Hyland C, Park JO, et al. Science 2007 316 1039 1043 10.1126/science.1141478 17463250 (Pubitemid 46799492)
20. The Wnt signaling pathway and its role in tumor development. Lustig B, Behrens J, J Cancer Res Clin Oncol 2003 129 199 221 12707770 (Pubitemid 36713796)
21. WNT/PCP signaling pathway and human cancer [review]. Katoh M, Oncol Rep 2005 14 1583 1588 16273260
22. Beta-Catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. Hoschuetzky H, Aberle H, Kemler R, J Cell Biol 1994 127 1375 1380 10.1083/jcb.127.5.1375 7962096 (Pubitemid 24362569)
23. Synchronous Alterations of Wnt and Epidermal Growth Factor Receptor Signaling Pathways through Aberrant Methylation and Mutation in Non -Small Cell Lung Cancer. Suzuki M, Shigematsu H, Nakajima T, Kubo R, Motohashi S, Sekine Y, et al. Clin Cancer Res 2007 13 6087 6092 10.1158/1078-0432.CCR-07-0591 17947472 (Pubitemid 350075066)
24. New guidelines to evaluate the response to treatment in solid tumors. Therasse P, Arbuck SG, Eisenhauer EA, et al. J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437 (Pubitemid 30099779)
25. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Mazieres J, He B, You L, Xu ZD, Lee AY, Mikami I, et al. Cancer Res 2004 64 4717 4720 10.1158/0008-5472.CAN-04-1389 15256437 (Pubitemid 38924512)
26. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, et al. Oncogene 2001 20 27 3528 3532 10.1038/sj.onc.1204455 11429699 (Pubitemid 32619405)
27. Aberrant methylation of E-cadherin and H-cadherin genes in non-small cell lung cancer and its relation to clinicopathologic features. Lee SM, Kim MJ, Lee JY, Park JY, Kim DS, Cancer 2007 12 2785 2792
28. Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer. Bai H, Mao L, Wang SH, Zhao J, Yang L, An TT, et al. J Clin Oncol 2009 27 2653 2659 10.1200/JCO.2008.17.3930 19414683
29. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Griffiths EA, Gore SD, Hooker C, McDevitt MA, Karp JE, Smith BD, et al. Leuk Lymphoma 2010 51 9 1711 1719 10.3109/10428194.2010.496505 20795789
30. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Su HY, Lai HC, Lin YW, Liu VY, Chen CK, Chou YC, et al. Int J Cancer 2010 127 3 555 567 10.1002/ijc.25083 19957335
31. Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MT1-MMP in gastric cancer. Zhao C, Bu X, Zhang N, Wang W, BMC Cancer 2009 9 224 10.1186/1471-2407-9-224 19586554
32. Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Sogabe Y, Suzuki H, Toyota M, Ogi K, Imai T, Nojima M, et al. Int J Oncol 2008 32 6 1253 1261 18497987
33. Hypermethylation and aberrant expression of secreted frizzled-related protein genes in pancreatic cancer. Bu XM, Zhao CH, Zhang N, Gao F, Lin S, Dai XW, World J Gastroenterol 2008 14 21 3421 3424 10.3748/wjg.14.3421 18528941
34. Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knuchel R, et al. Carcinogenesis 2008 29 5 991 998 10.1093/carcin/bgn076 18356147 (Pubitemid 351982244)
35. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Minke KS, Staib P, Puetter A, Gehrke I, Gandhirajan RK, Schlösser A, et al. Eur J Haematol 2009 82 3 165 175 10.1111/j.1600-0609.2008.01188.x 19067737
36. DNA methylation and cancer therapy: new developments and expectations. Esteller M, Curr Opin Oncol 2005 17 1 55 60 10.1097/01.cco.0000147383.04709.10 15608514 (Pubitemid 40179913)